Boehringer Ingelheim: Board Change

Boehringer Ingelheim: Board Change

13.11.2012 - Allan Hillgrove will take over Engelbert Tjeenk Willink's responsibilities on the firms board and as its Managing Director of Division Marketing and Sales Prescription as of 1 January 2013.

Willink, Member of the Board of Managing Directors at Boehringer Ingelheim GmbH and responsible for Marketing and Sales of Prescription Medicines since 2009, has decided to leave the pharma major and global contract manufacturer at the end of 2012. The native Australian (52), who joined the Boehringer Group in 1982, became Head of Established Markets in 2010. Willink worked as Head of Marketing for Prescription Medicines at Boehringer from 2001-2005. Before that he acted as Head of Marketing and Sales in Canada, and from 2005-2008 he worked as Country Manager of Boehringer Ingelheim Mexico. Last year, the pharma giant achieved net sales of over 13bn. R&D expenditure in the business area Prescription Medicines, the marketing area that will now be led by Hillgrove, corresponded to 23.5% of the company’s net sales.

18.09.2012 German oncology expert Wilex AG has altered its executive management board. Dr. Jan Schmidt-Brand, who arrived from Wilex daughter Heidelberg Pharma, stepped into the CFO role at Wilex at the beginning of September.

Schmidt-Brandt was Managing Director at Heidelberg Pharma, which develops antibody-drug conjugates, until that firm was taken over by Wilex in November 2010. From 1997-2001, the trained lawyer was Managing Director of the Austrian BASF-Pharma subsidiary EBEWE Arznei-mittel GmbH, where his responsibilities included finance and controlling. Prior to that, he held several positions at the BASF Group over a period of eight years. In his final position there he was an executive in the chemical giant's central tax department. At the beginning of August, the firm announced that current CFO Peter Llewellyn-Davies would be stepping down when his six-year contract expired. Wilex announced that he is planning to pursue new activities, but will continue to act for the company in an advisory capacity.

14.09.2012 French-US non-statistical clinical data analyses provider Ariana Pharma has hired Dr. Mariana Kuras as its Chief Technology Officer.

From 2004–2012, Kuras led research at Bio-systems International, where she was responsible for the development and validation of biomarker platform technologies with the help of anti-body array technologies. Previously, she worked at Pfizer Global Research and Development (Fresnes, France). Kuras holds a PhD in biophysics and computational biology from the University of Illinois at Urbana-Champaign in the US.

12.09.2012 Oslo-based Photocure ASA has named Erik Dahl as its new CFO.

The specialist for photodynamic skin and cancer therapy brings more than 20 years of experience in senior level financial management roles in both international public and private companies. He has a strong track record in corporate finance, legal and financial restructurings, M&A, IPOs and other capital market transactions.

24.09.2012 Belgian chondrocyte therapy specialist TiGenix BV (Leuven) has named Jean Stéphenne as its Independent Director and new Chairman of the Board.

Previously, Stéphenne was a member of the executive team at GlaxoSmithKline, and Chairman and President of GSK Biologicals in Wavre (Belgium). He currently serves as Chairman of BESIX, IBA & BioWin, and Vesalius Biocapital.

28.09.2012 Dutch Mucosis B.V. (Groningen) has named Thomas Johnston as its new Chief Executive Officer with immediate effect.

The vaccine developer's former CBO succeeds Govert Schouten, who founded an Internet start-up. Johnston joined Mucosis from Novavax Inc. in 2011, where he served as Vice President of Strategy. Prior to Novavax, Johnston was a consultant in various industries, including biotech.

01.10.2012 siRNA specialist Silence Therapeutics plc (London/Berlin) has appointed Michael Khan to its board of directors as Chief Medical Advisor.

Khan, who currently teaches and works as an Associate Professor of Medicine at the University of Warwick, has a strong track record in clinical development of drugs targeting metabolic diseases and cancer. The previous head of molecular medicine at Warwick University is currently working on identifying novel tissue-based biomarkers for colorectal cancer, and the development of novel diagnostic tools.

09.10.2012 Philip Astley-Sparke, previous President and CEO of BioVex, has become a venture partner in Forbion Capital Partners’ Boston office.

He will work with selected Forbion’s portfolio companies as a board member and/or advisor to help management to execute on their business plans. Until late 2011, the investment banker (JP Morgan) and biologist (BSc, Bristol University) worked with Amgen as its Vice President and General Manager after his former firm Biovex had been acquired by Amgen in a US$ 1bn deal. Forbion was the largest investor in the US-based developer of first-in-class oncolytic vaccines.

16.10.2012 Austrian Medtech provider Anagnostics has hired Karl Winkler (48), a marketing expert for medical devices.

Winkler brings in 20 years of marketing, 11 of which as a medtech distribution specialist. Winkler is specialised in drug analytics and will start marketing Anagnostic’s hybcell technology in Germany, Switzerland and Austria.

12.10.2012 Berlin-based diagnostics specialist Epigenomics AG has named its current Chief Financial Officer Dr. Thomas Taapken as the new Chief Executive Officer, effective 1 October 2012.

He will replace Geert Nygaard who will leave the Executive Management of the company. “On behalf of the Board of Directors, I would like to thank Geert Nygaard for his dedication to the Company for the past five and half years", said Heino von Prondzynski, Epigenomics’ Chairman of the Board. Prodzynski, a former Head of Roche Diagnostics, joined the company's board in March this year. He is regarded as a renowned industry expert. Epigenomics has faced several changes in the company's business strategy in the recent years. Taapken joined Epigenomics in April 2011 as Chief Financial Officer from Biotie Therapies (Finland). From 2005-2008 Taapken worked with elbion NV, which was then acquired by Biotie Therapies.

19.10.2012 Dr Christian Itin has been appointed CEO of Swiss biologics developer Cytos Biotechnology Ltd, (Zurich).

Itin headed German-based Micromet before it was taken over in a US$1.16bn deal by Amgen. In May, Cytos announced it had chosen the 48-year-old to succeed Thomas Hecht as its Chairman of the Board of Directors after an extraordinary shareholders meeting scheduled to take place in November 2012. Before Itin’s stint at the Micromet helm, he worked with California-based protein array specialist Zyomyx. Inc (Hayward). He received his Diplom in biology and Ph.D. in cell biology from the University of Basel. In addition, Christian Itin performed post-doctoral research at Basel University’s Biocenter and at the Stanford University School of Medicine.

Vorherige Seite4/6Nächste Seite

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Product of the week



All videos


All Events

Stock list

All quotes


  • 4SC1.28 EUR10.34%
  • BASILEA110.70 CHF2.31%
  • BIOTEST98.10 EUR2.29%


  • PAION2.36 EUR-6.72%
  • MOLOGEN5.45 EUR-4.22%
  • WILEX3.01 EUR-2.90%


  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.31 EUR189.6%
  • 4SC1.28 EUR64.1%


  • MORPHOSYS58.81 EUR-21.3%
  • WILEX3.01 EUR-12.2%
  • BASILEA110.70 CHF-9.4%


  • SANTHERA93.75 CHF2214.8%
  • FORMYCON26.94 EUR271.6%
  • WILEX3.01 EUR220.2%


  • CYTOS1.43 CHF-52.3%
  • MOLOGEN5.45 EUR-52.0%
  • PAION2.36 EUR-35.0%

No liability assumed, Date: 31.03.2015

Current issue

All issues